Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Enterprise Value (2021 - 2025)

Prime Medicine filings provide 5 years of Enterprise Value readings, the most recent being -$177.7 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 5.21% to -$177.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$177.7 million, a 5.21% increase, with the full-year FY2025 number at -$177.7 million, up 5.21% from a year prior.
  • Enterprise Value hit -$177.7 million in Q4 2025 for Prime Medicine, up from -$208.4 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$48.8 million in Q3 2023 to a low of -$286.1 million in Q4 2022.
  • Median Enterprise Value over the past 5 years was -$167.4 million (2022), compared with a mean of -$156.1 million.
  • The widest YoY moves for Enterprise Value: up 70.04% in 2024, down 249.8% in 2024.
  • Prime Medicine's Enterprise Value stood at -$117.7 million in 2021, then plummeted by 142.99% to -$286.1 million in 2022, then skyrocketed by 59.38% to -$116.2 million in 2023, then plummeted by 61.29% to -$187.4 million in 2024, then rose by 5.21% to -$177.7 million in 2025.
  • The last three reported values for Enterprise Value were -$177.7 million (Q4 2025), -$208.4 million (Q3 2025), and -$98.3 million (Q2 2025) per Business Quant data.